{
  "nct_id": "NCT28650056",
  "indication": "COPD",
  "phase": "Phase 3",
  "sample_size": 703,
  "duration_weeks": 37,
  "dropout_rate": 0.27,
  "blinding": "double-blind",
  "control_arm": "placebo",
  "primary_endpoints": [
    "SGRQ score improvement"
  ],
  "secondary_endpoints": [
    "Exacerbation reduction",
    "FEV1 improvement"
  ],
  "outcome_summary": "No significant difference compared to placebo",
  "success": 0,
  "failure_reason": "Drug-drug interactions affected efficacy",
  "start_date": "2024-01-19",
  "completion_date": "2024-10-04"
}